Phase Forward Delivers Enhanced Integration Capabilities as Part of Ongoing Adapter Strategy; InForm(TM) Adapter, Available Immediately, Strengthens Integration with Existing Customer Data and Systems.

WALTHAM, Mass. -- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced the new InForm(TM) Adapter module, providing customers with enhanced integration capabilities for the InForm Integrated Trial Management (ITM) electronic data capture (EDC) solution. With the InForm Adapter module, InForm ITM users can leverage a set of Web services-based interfaces to access data and event information stored in the InForm database. The result is a broader set of integrated and extensible clinical workflow solutions that better leverage InForm ITM users' existing proprietary systems and packaged applications.

The announcement reflects the company's strategy to deliver greater integration and extensibility for Phase Forward customers through adapters. Providing adapters that leverage Web services standards creates an architecture that allows more integration points to be added more quickly in the future. "Our customers have asked us for greater interoperability between their internal systems and the InForm ITM solution," said Steve Rosenberg, Phase Forward's senior vice president. "More fluent integration between the systems introduces significant productivity enhancements, creating time-saving and cost-reduction opportunities. With the InForm Adapter we are delivering this extensibility directly into the hands of our customers."

Through the use of a set of available Web service interfaces, the InForm Adapter module enables customers to build routines that leverage their study data and events to interoperate with other business systems such as clinical, custom, financial, ERP and inventory management systems. Available interfaces include:

--Operational Data Management (ODM) Export Interface: exports InForm clinical and metadata in Clinical Data Interchange Standards Consortium (CDISC) ODM XML format, delivering standards-based, system-to-system communication

--Discrepancy Interface: enables bi-directional transmission of InForm clinical data queries (discrepancies) and managed workflow to and from other source systems

--Event Interface: publishes particular events (such as status changes and data changes) when they occur in InForm that can be used to trigger routines in other systems such as processing payments or initiating inventory orders

--Coding Interface: enables outbound transmission of InForm adverse event, drug and medical history verbatims to an external coding application, and inbound receipt of coded values back to the InForm database

The InForm Adapter module is versioned independently to provide maximum maintenance and upgrade flexibility, shortening customer development time, reducing integration costs and streamlining the integration validation process. Security is assured through the use of standards-based Secure Sockets Layer (SSL) certificates, Windows authentication and Security Assertion Markup Language (SAML) authentication and authorization.

Pricing and Availability

The InForm Adapter module is available immediately at no charge to Phase Forward InForm ITM customers. Nominal hosting fees are applicable when the InForm Adapter module is deployed in the Phase Forward hosting facility.

For more details on the InForm Adapter, visit: www.phaseforward.com

About Phase Forward

Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InForm(TM)), clinical data management (Clintrial(TM)), clinical trials signal detection (CTSD(TM)), strategic pharmacovigilance (WebVDME(TM) and Signal Management), adverse event reporting (Clintrace(TM)) and applied data standards (WebSDM). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward's products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 230 organizations and regulatory agencies worldwide including: AstraZeneca, Biogen Idec, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, Food and Drug Administration, GlaxoSmithKline, Guidant, Merck, U.K. Medicines and Healthcare Products Regulatory Agency, National Institutes of Health, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute and Serono. Additional information about Phase Forward is available at www.phaseforward.com.

Certain statements made in this press release that are not based on historical information are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains express or implied forward-looking statements relating to, among other things, the performance and features of Phase Forward's products and services, the ability of Phase Forward's customers to realize benefits from the use of these products and services, and the continued availability of complementary technologies and their compatibility with Phase Forward's products. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond Phase Forward's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things, the ability of Phase Forward's customers to realize benefits from the use of its products and services, changes in complementary technologies, changes in commonly used industry standards, and the possibility that customers' needs or plans may change over time. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Phase Forward undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Phase Forward, see the disclosure contained in Phase Forward's public filings with the Securities and Exchange Commission including, without limitation, its most recent Quarterly Report on Form 10-Q.